Day One Biopharmaceuticals
DAWN
DAWN
168 hedge funds and large institutions have $602M invested in Day One Biopharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 60 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
1.61% less ownership
Funds ownership: 85.03% → 83.42% (-1.6%)
3% less funds holding
Funds holding: 174 → 168 (-6)
12% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 60
Holders
168
Holding in Top 10
4
Calls
$641K
Puts
$432K
Top Buyers
| 1 | +$23.8M | |
| 2 | +$10.7M | |
| 3 | +$10.2M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.76M |
| 5 |
DM
Deerfield Management
New York
|
+$6.93M |
Top Sellers
| 1 | -$13.7M | |
| 2 | -$9.51M | |
| 3 | -$8.78M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.35M |
| 5 |
BlackRock
New York
|
-$5.84M |
